Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
Author: Global Cancer Consortium
One type of nanoparticle currently in development engages in “active targeting,” or targeting drugs to cancer cells by attaching them to a molecule that the cancer cell is receptive to.
The company is a medical devices company that has developed an apparatus for advanced diagnostic analysis of cervical tissue, which serves as a routine screening test for women’s cervical cancer. This unique cervical sampling device is able to achieve a 360 degree collection of the entire cervix thereby enhancing the sampling quality and its diagnostic value. This device is poised to replace the traditional Pap smear which is currently used for women’s cervical screening. Click here for more information
The company is a medical devices company that has developed a novel therapeutic approach for ablation of solid tumors in cancer patients. The technology uses Auroshell nano-particles that are inert material particles that absorb and convert laser energy into heat. The particles are delivered to patients systemically, and an interstitial fiber optic probe is subsequently used to deliver laser energy to indicated sites destroying tumors without damaging adjacent tissue. This technology avoids the systemic toxicity of traditional chemotherapy, and is poised to serve as adjunct in cancer treatments. Click here for more information
The company is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant and malignant cells. Unlike traditional tests that detect cell tumor lumps in the breast when cancer has advanced into a mature state, this test can detect cancer risk years before tumor build up. The test is a non-invasive, 5 minute procedure that is fully automated and can be used in busy primary care settings, yet still provides doctors with advanced diagnostic results. Click here for more information
On May 21, 2010 Pressure BioSciences, Inc. (NasdaqCM: PBIO) sponsored a symposium at Harvard Medical School on the “Applications of Ultra-High Pressure in Technology.”
A number of companies are developing minimally invasive devices that produce the weight-reducing effects of a gastric bypass minus the actual surgery.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.